Sugi Predict

Sugi Predict / Compounds / SCHEMBL20542017

SCHEMBL20542017

SCHEMBL20542017

CC(C)n1cnc2c(NCCc3cn(C)c4ccccc34)nc(-c3cncc(F)c3)nc21

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ AHR P35869 1/20 0.45
▸ CDK1 P06493 9/20 0.42
▸ CDK5 Q00535 8/20 0.42
▸ CDK5R1 Q15078 7/20 0.42
▸ CCNB2 O95067 6/20 0.42
▸ CCNB1 P14635 6/20 0.42
▸ CCNB3 Q8WWL7 6/20 0.42
▸ IP6K1 Q92551 1/20 0.40
▸ CCNE2 O96020 4/20 0.39
▸ CCNE1 P24864 4/20 0.39
▸ CDK2 P24941 4/20 0.39
▸ CCNK O75909 2/20 0.39
▸ CDK12 Q9NYV4 2/20 0.39
▸ NPC1 O15118 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ CCNA2 P20248 3/20 0.38
▸ CCNA1 P78396 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30579387 1.00 AHR (0.45) AHRCDK1CDK5CDK5R1CCNB2
SCHEMBL28359163 0.85 CDK2 (0.39) CDK1CDK5CDK5R1CCNB2CCNB1
SCHEMBL2358698 0.85 CCNE2 (0.56) AHRCDK1CDK5CDK5R1CCNB2
SCHEMBL28359160 0.84 CDK2 (0.37) AHRCDK1CDK5CDK5R1CCNB2
SCHEMBL2358550 0.83 CDK2 (0.44) AHRCDK1CDK5CDK5R1CCNB2
SCHEMBL20541795 0.82 CDK1 (0.43) AHRCDK1CDK5CDK5R1CCNB2
SCHEMBL2316607 0.82 CDK2 (0.44) AHRCDK1CDK5CDK5R1CCNB2
SCHEMBL30315335 0.82 CDK2 (0.44) AHRCDK1CDK5CDK5R1CCNB2
SCHEMBL2358503 0.81 CDK2 (0.43) AHRCDK1CDK5CDK5R1CCNB2
SCHEMBL2356743 0.81 AHR (0.43) AHRCDK1CDK5CDK5R1CCNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4710923-A2 INDOLE AHR INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2026-03-18 — — EP disclosed
EP-3612030-B1 INDOLE AHR INHIBITORS AND USES THEREOF IKENA ONCOLOGY INC (US) 2025-12-24 — — EP disclosed
US-20250122205-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2025-04-17 — — US disclosed
US-12077542-B2 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2024-09-03 — — US disclosed
US-20230028336-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2023-01-26 — — US disclosed
US-20230028336-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2023-01-26 — — US disclosed
US-11358969-B2 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2022-06-14 — — US disclosed
US-11358969-B2 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2022-06-14 — — US disclosed
US-20200331917-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2020-10-22 — — US disclosed
US-20200331917-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2020-10-22 — — US disclosed
US-10689388-B1 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2020-06-23 — — US disclosed
US-10689388-B1 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2020-06-23 — — US disclosed
EP-3612030-A2 INDOLE AHR INHIBITORS AND USES THEREOF Kyn Therapeutics (US) 2020-02-26 — — EP disclosed
US-10570138-B2 Indole AHR inhibitors and uses thereof KYN THERAPEUTICS (US) 2020-02-25 — — US disclosed
US-10570138-B2 Indole AHR inhibitors and uses thereof KYN THERAPEUTICS (US) 2020-02-25 — — US disclosed
CN-110831600-A Indole AHR inhibitors and uses thereof 金恩医疗公司 2020-02-21 — — CN disclosed
US-20180327411-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2018-11-15 — — US disclosed
WO-2018195397-A2 INDOLE AHR INHIBITORS AND USES THEREOF KYN THERAPEUTICS (US) 2018-10-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180327411-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 AHR 1/4885CDK1 2497/4885CDK5 1931/4885
US-10570138-B2 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 AHR 1/4885CDK1 2497/4885CDK5 1931/4885
US-11358969-B2 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 AHR 1/4885CDK1 2497/4885CDK5 1931/4885
US-20200331917-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 AHR 1/4885CDK1 2497/4885CDK5 1931/4885
US-10689388-B1 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 AHR 1/4885CDK1 2497/4885CDK5 1931/4885
US-20250122205-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 AHR 1/4885CDK1 2497/4885CDK5 1931/4885
US-20230028336-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 AHR 1/4885CDK1 2497/4885CDK5 1931/4885
US-12077542-B2 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 AHR 1/4885CDK1 2497/4885CDK5 1931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback